Drug Profile
SU 14813
Alternative Names: SU 014813; SU-14,813Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 27 Sep 2010 Discontinued - Phase-II for metastatic Breast cancer in European Union (PO)
- 27 Sep 2010 Discontinued - Phase-II for metastatic Breast cancer in USA (PO)
- 03 Jun 2008 Interim efficacy and adverse events data from a phase I trial in Solid tumours presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)